Increased incidence of hospitalization for heart failure (HHF) among patients with diabetes is increasingly being reported. We investigated the incidence of adverse cardiovascular events including HHF among patients with type 2 diabetes mellitus, and the potential clinical improvement with sodium–glucose cotransporter 2 inhibitors (SGLT2i) using a contemporary administrative claims database from a large governmental district… Continue reading Incidence of adverse #cardiovascular events in type 2 #diabetes mellitus patients after initiation of glucose‐lowering agents: A population‐based community study from the Shizuoka Kokuho database
Category: Endocrinology
#Metformin Use Is Associated With Reduced Mortality in a Diverse Population With #COVID-19 and Diabetes
Coronavirus disease-2019 (COVID-19) is a growing pandemic with an increasing death toll that has been linked to various comorbidities as well as racial disparity. However, the specific characteristics of these at-risk populations are still not known and approaches to lower mortality are lacking.. ..The odds ratio of contracting COVID-19 was disproportionately high in Blacks/African-Americans (OR… Continue reading #Metformin Use Is Associated With Reduced Mortality in a Diverse Population With #COVID-19 and Diabetes
EUGLYCEMIC DIABETIC #KETOACIDOSIS WITH #COVID-19 INFECTION IN PATIENTS WITH TYPE 2 DIABETES TAKING #SGLT2 INHIBITORS
Diabetes mellitus is associated with poor outcomes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Diabetic ketoacidosis (DKA) has also been reported to occur with this virus. A cluster of cases of euglycemic DKA (euDKA) was identified in patients with type 2 diabetes mellitus using sodium-glucose cotransporter-2 inhibitors (SGLT2is) who developed SARS-CoV-2 infection.. ..Five… Continue reading EUGLYCEMIC DIABETIC #KETOACIDOSIS WITH #COVID-19 INFECTION IN PATIENTS WITH TYPE 2 DIABETES TAKING #SGLT2 INHIBITORS
A randomized controlled trial of 130 g/day low-#carbohydrate diet in type 2 #diabetes with poor glycemic control
The usefulness of low-carbohydrate diet (LCD) for Japanese patients with type 2 diabetes mellitus (T2DM) has not been fully investigated. Therefore, we compared the effectiveness and safety of LCD with calorie restricted diet (CRD). This prospective, randomized, open-label, comparative study included 66 T2DM patients with HbA1c >7.5% even after receiving repeated education programs on CRD.… Continue reading A randomized controlled trial of 130 g/day low-#carbohydrate diet in type 2 #diabetes with poor glycemic control
Efficacy and safety of #linagliptin in type 2 #diabetes patients with self-reported #hepatic disorders: A retrospective pooled analysis of 17 randomized, double-blind, placebo-controlled clinical trials
Liver disease is highly prevalent among people with type 2 diabetes mellitus (T2DM). We evaluated the dipeptidyl peptidase-4 inhibitor linagliptin in subjects with T2DM and hepatic disorders.. ..Of the 7009 participants (56% white, 39% Asian), 574 had hepatic disorders, most commonly hepatic steatosis (60%). At week 24, adjusted mean ± standard error (SE) change in… Continue reading Efficacy and safety of #linagliptin in type 2 #diabetes patients with self-reported #hepatic disorders: A retrospective pooled analysis of 17 randomized, double-blind, placebo-controlled clinical trials
#Plastics, #EDCs & Health: Authoritative Guide
The Endocrine Society and IPEN (International Pollutants Elimination Network) are proud to present this authoritative and comprehensive report to addresses how plastics can harm human health. An expert overview of twenty years of research shows that plastics pose a threat to public health because they contain a host of hazardous, endocrine-disrupting chemicals (EDCs) that leach… Continue reading #Plastics, #EDCs & Health: Authoritative Guide
Advanced #Liver Fibrosis Is Common in Patients With Type 2 #Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
Assess the prevalence of nonalcoholic fatty liver disease (NAFLD) and of liver fibrosis associated with nonalcoholic steatohepatitis in unselected patients with type 2 diabetes mellitus (T2DM). A total of 561 patients with T2DM (age: 60 ± 11 years; BMI: 33.4 ± 6.2 kg/m2; and HbA1c: 7.5 ± 1.8%) attending primary care or endocrinology outpatient clinics… Continue reading Advanced #Liver Fibrosis Is Common in Patients With Type 2 #Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
#Dapagliflozin and the Incidence of Type 2 #Diabetes in Patients With #Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF
The sodium–glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of cardiovascular mortality and worsening heart failure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial. This report explores the effect of dapagliflozin on incident type 2 diabetes (T2D) in the cohort without diabetes enrolled in the trial RESEARCH DESIGN AND METHODS… Continue reading #Dapagliflozin and the Incidence of Type 2 #Diabetes in Patients With #Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF
Vitamin #D metabolites and the gut #microbiome in older men
The vitamin D receptor is highly expressed in the gastrointestinal tract where it transacts gene expression. With current limited understanding of the interactions between the gut microbiome and vitamin D, we conduct a cross-sectional analysis of 567 older men quantifying serum vitamin D metabolites using LC-MSMS and defining stool sub-Operational Taxonomic Units from16S ribosomal RNA… Continue reading Vitamin #D metabolites and the gut #microbiome in older men
2 Medical News 